Get the Stockscreener App
15.24
5.34%
-0.86
After Hours:
14.20
-1.04
-6.82%
Seres Therapeutics Inc stock is traded at $15.24, with a volume of 112.11K.
It is down -5.34% in the last 24 hours and down -25.98% over the past month.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
See More
Previous Close:
$16.10
Open:
$16.05
24h Volume:
112.11K
Relative Volume:
0.71
Market Cap:
$133.42M
Revenue:
$123.24M
Net Income/Loss:
$136.00K
P/E Ratio:
-762.00
EPS:
-0.02
Net Cash Flow:
$-148.99M
1W Performance:
-11.24%
1M Performance:
-25.98%
6M Performance:
+58.26%
1Y Performance:
-7.29%
1-Day Range:
$15.08
$16.66
1-Week Range:
$15.08
$17.40
52-Week Range:
$6.53
$24.67
Seres Therapeutics Inc Stock (MCRB) Company Profile
Name
Seres Therapeutics Inc
Sector
Industry
Phone
617 945 9626
Address
200 SIDNEY STREET, CAMBRIDGE, MA
Compare MCRB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
15.24 | 140.95M | 123.24M | 136.00K | -148.99M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-08-25 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-24-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Apr-21-23 | Initiated | JP Morgan | Neutral |
| Jul-23-21 | Downgrade | Goldman | Neutral → Sell |
| May-18-21 | Resumed | Goldman | Neutral |
| Mar-05-21 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Sep-18-20 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-11-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-11-20 | Upgrade | Jefferies | Hold → Buy |
| Apr-30-19 | Initiated | Jefferies | Hold |
| Oct-22-18 | Initiated | Chardan Capital Markets | Buy |
| Oct-13-17 | Initiated | Oppenheimer | Outperform |
| Aug-04-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-01-17 | Reiterated | FBR & Co. | Outperform |
| Aug-12-16 | Reiterated | FBR Capital | Outperform |
| Aug-01-16 | Downgrade | BofA/Merrill | Buy → Neutral |
| Aug-01-16 | Reiterated | H.C. Wainwright | Buy |
| Jul-29-16 | Resumed | H.C. Wainwright | Buy |
| Mar-30-16 | Initiated | FBR Capital | Outperform |
| Mar-03-16 | Initiated | Guggenheim | Buy |
| Jan-25-16 | Initiated | H.C. Wainwright | Buy |
| Oct-22-15 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-22-15 | Initiated | Canaccord Genuity | Buy |
| Jul-21-15 | Initiated | Goldman | Neutral |
| Jul-21-15 | Initiated | Leerink Partners | Outperform |
View All
Seres Therapeutics Inc Stock (MCRB) Latest News
Analyzing Seres Therapeutics Inc. with risk reward ratio chartsJuly 2025 EndofMonth & Reliable Volume Spike Trade Alerts - newser.com
Will Seres Therapeutics Inc. (1S90) stock extend growth storyTrade Ideas & Daily Stock Trend Reports - newser.com
Is Seres Therapeutics Inc. stock supported by innovation pipeline2025 Volatility Report & Daily Growth Stock Investment Tips - newser.com
How interest rate cuts could boost Seres Therapeutics Inc. stockJuly 2025 Patterns & AI Forecast Swing Trade Picks - newser.com
What market sentiment indicators show for Seres Therapeutics Inc. (1S90) stock2025 Market WrapUp & Accurate Buy Signal Alerts - newser.com
Can volume confirm reversal in Seres Therapeutics Inc.2025 Market Trends & Low Risk High Win Rate Stock Picks - newser.com
Will Seres Therapeutics Inc. stock split attract more investorsJuly 2025 Spike Watch & Reliable Price Action Trade Plans - newser.com
Is Seres Therapeutics Inc. stock a contrarian buy2025 Historical Comparison & Stepwise Swing Trade Plans - newser.com
Key metrics from Seres Therapeutics Inc.’s quarterly data2025 Market Trends & Weekly High Return Stock Forecasts - newser.com
Published on: 2025-11-03 00:21:05 - newser.com
Published on: 2025-11-02 23:51:16 - newser.com
Is Seres Therapeutics Inc. stock recession proof2025 Year in Review & Daily Stock Trend Reports - newser.com
Analyzing Seres Therapeutics Inc. with multi timeframe chartsDollar Strength & Risk Managed Investment Strategies - newser.com
Institutional scanner results for Seres Therapeutics Inc.July 2025 WrapUp & Verified Chart Pattern Trade Signals - newser.com
Seres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Below Fifty Day Moving AverageTime to Sell? - MarketBeat
Is Seres Therapeutics Inc. stock attractive for hedge fundsEarnings Recap Summary & High Conviction Buy Zone Picks - newser.com
Backtesting results for Seres Therapeutics Inc. trading strategiesWeekly Profit Report & Safe Capital Growth Stock Tips - newser.com
Is Seres Therapeutics Inc. stock a buy on dipsPrice Action & Reliable Volume Spike Trade Alerts - newser.com
Seres Therapeutics (MCRB) to Release Earnings on Wednesday - MarketBeat
Published on: 2025-11-01 01:46:58 - newser.com
How Seres Therapeutics Inc. (1S90) stock moves on employment dataExit Point & Daily Stock Trend Reports - newser.com
Operating cash flow per share of Seres Therapeutics Inc – BX:MCRB - TradingView
Is Seres Therapeutics Inc. (1S90) stock a buy before earnings resultsWeekly Profit Analysis & AI Enhanced Trading Alerts - newser.com
Published on: 2025-10-31 04:08:39 - newser.com
News impact scoring models applied to Seres Therapeutics Inc.Quarterly Portfolio Summary & Long-Term Safe Investment Plans - newser.com
Seres Therapeutics, Inc. (MCRB) Stock Price, News, Quote & History - Yahoo! Finance Canada
Seres Therapeutics (MCRB) Price Target Decreased by 62.44% to 16.32 - MSN
Leading vs lagging indicators on Seres Therapeutics Inc. performanceEarnings Overview Summary & Low Volatility Stock Suggestions - newser.com
Published on: 2025-10-30 06:05:42 - newser.com
Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025 - MarketScreener
Nov. 5 at 8:30 a.m. ET: Seres Therapeutics (NASDAQ: MCRB) hosts third-quarter results call - Stock Titan
Published on: 2025-10-30 04:27:10 - newser.com
Seres Therapeutics Inc Stock (MCRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):